Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$1.02 - $3.23 $67 - $213
66 Added 0.2%
33,110 $41,000
Q4 2023

Feb 13, 2024

SELL
$1.72 - $3.18 $228 - $422
-133 Reduced 0.4%
33,044 $90,000
Q3 2023

Nov 13, 2023

BUY
$2.13 - $5.55 $2,513 - $6,549
1,180 Added 3.69%
33,177 $75,000
Q2 2023

Aug 04, 2023

BUY
$3.6 - $5.25 $115,189 - $167,984
31,997 New
31,997 $139,000
Q2 2022

Aug 12, 2022

SELL
$2.6 - $6.14 $45,793 - $108,143
-17,613 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$5.08 - $9.81 $6,294 - $12,154
-1,239 Reduced 6.57%
17,613 $100,000
Q4 2021

Feb 11, 2022

SELL
$8.55 - $111.89 $2,368 - $30,993
-277 Reduced 1.45%
18,852 $185,000
Q3 2021

Nov 12, 2021

SELL
$76.53 - $110.43 $34,744 - $50,135
-454 Reduced 2.32%
19,129 $2.03 Million
Q2 2021

Aug 13, 2021

BUY
$85.37 - $114.1 $367,091 - $490,630
4,300 Added 28.14%
19,583 $1.67 Million
Q1 2021

May 07, 2021

BUY
$109.73 - $153.66 $4,389 - $6,146
40 Added 0.26%
15,283 $1.75 Million
Q4 2020

Feb 12, 2021

BUY
$79.58 - $152.45 $54,034 - $103,513
679 Added 4.66%
15,243 $2.13 Million
Q3 2020

Nov 04, 2020

SELL
$66.43 - $90.99 $21,921 - $30,026
-330 Reduced 2.22%
14,564 $1.19 Million
Q2 2020

Aug 12, 2020

BUY
$44.04 - $80.69 $148,194 - $271,521
3,365 Added 29.19%
14,894 $1.07 Million
Q1 2020

May 04, 2020

SELL
$44.49 - $93.39 $29,630 - $62,197
-666 Reduced 5.46%
11,529 $513,000
Q4 2019

Feb 05, 2020

SELL
$66.49 - $137.73 $6,781 - $14,048
-102 Reduced 0.83%
12,195 $1.16 Million
Q3 2019

Nov 08, 2019

BUY
$31.0 - $89.73 $39,246 - $113,598
1,266 Added 11.48%
12,297 $967,000
Q2 2019

Aug 13, 2019

BUY
$36.0 - $44.73 $70,992 - $88,207
1,972 Added 21.77%
11,031 $478,000
Q1 2019

May 06, 2019

BUY
$33.79 - $51.99 $119,346 - $183,628
3,532 Added 63.9%
9,059 $367,000
Q4 2018

Feb 13, 2019

BUY
$31.59 - $62.65 $1,074 - $2,130
34 Added 0.62%
5,527 $289,000
Q3 2018

Nov 09, 2018

BUY
$31.25 - $47.64 $171,656 - $261,686
5,493 New
5,493 $247,000

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $54.2M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.